Latest News

Add to Favorites | Subscribe | Share


  • (Press "esc" to clear)


Life Sustaining, Support, Intensive, care, Resusitate Sleep, Disordered, Breathing, Apnea, African American

January Tip Sheet from American Thoracic Society

The following stories appear in the January issue of the American Thoracic Society's (ATS) American Journal of Respiratory and Critical Care Medicine. 1 - Withdrawing life support from terminally ill patients reportedly more routinely accepted by physicians and patient families. 2 - Sleep disordered breathing found to be twice as prevalent among African Americans than Caucasians. Embargoed For Release: January 16, 1997 6:00 p.m.


Apples, Color, Taste, Chemistry, Volatile, Esters, Flavor, Storage

The Color of Apples Can Affect Their Taste

It is one of those last gorgeous days of October, and John Fellman is leading me through the variety block of WSU's Tukey Orchard, 392 trees of 97 different varieties. The tastes are doing extraordinary things to my nose and taste buds. We are in apple heaven.


Breathing, Apneusis, Serotonin, Buspirone, Pediatrics, Apnea

New treatment found for severe breathing disorder

Research by an international team of scientists on brain chemicals that control breathing may have paid off for the stroke patients and brain-damaged children who most commonly suffer from apneusis. The hallmark of the dangerous and under-recognized disorder is an inability to exhale normally.


Plasma, Emory, Transgenics, Atiii, DNA, Bloodclots, Surgery

Genzyme Transgenics Begins U.S. Phase II Trial with ATIII

Genzyme Transgenics Corp. has begun a phase II clinical trial in the United States with its lead product, the transgenic form of human antithrombin III (ATIII), a plasma protein that helps prevent harmful blood clotting in many serious medical conditions. It is the first clinical trial in which patients will be treated with a product made in the milk of a transgenic animal.


Genetics, Therapy, Cardiovascular, Heart, Disease

Genzyme's Cardiovascular Gene Therapy Program

Genzyme Corp. has commenced a gene therapy program that will concentrate on the development of molecular therapies to treat cardiovascular disease. As an initial focus, the company will be working with scientists at Duke University and the University of California, San Diego (UCSD), to develop treatments for congestive heart failure, vein graft failure, and restenosis. Additionally, through its collaboration with UCSD, Genzyme will be developing a gene therapy application to protect heart tissue from oxygen damage that can occur during various types of cardiac procedures.


Hopkins, Biology, Ecology, Biodiversity

Review Copies Available of Book on Biodiversity

Review copies are available of a new Johns Hopkins University Press book on biodiversity. "The Idea of Biodiversity: Philosophies of Paradise" examines the concept of biodiversity, its origins and its impact on society.


Johns, Hopkins, Medicine, Scleroderma, Autoantibodies, Blood, Vessels, Immune, System

Scientists Find Early Clues Into Scleroderma

Johns Hopkins scientists studying scleroderma may have identified the unique molecular footprints on the biochemical trail leading the immune system to attack its own tissues.


Diffusion, Mir, Microgravity, Weightlessness

A golden chance to understand diffusion

A small gold oven sent to Russia's MIR space station may give scientists valuable insights into diffusive transport in liquids, a fundamental physical process that is so little understood that there are a half dozen conflicting theories about how the process actually works.


Product, Development, Competition, Japan, U.S., Electronics, Superiority

Survey Says Superior Products May Be Bad

Relatively small U.S. companies probably should not invest the money that is needed to develop industrial products which are technically superior and have superior performance.



Implants, Coatings, Orthopaedic, hip, Replacement

Coating process may give implants longer life

A process that bonds the stuff from which bones are made onto the surface of artificial bone and joint implants may give longer life to as many as 600,000 implants a year.

Chat now!